Hematopoietic stem cell transplantation for therapy-related myelodysplastic syndrome and acute leukemia

A single-center analysis of 47 patients

Hiroki Yokoyama, Shin Ichiro Mori, Yukio Kobayashi, Saiko Kurosawa, Bungo Saito, Shigeo Fuji, Dai Maruyama, Teruhisa Azuma, Sung Won Kim, Takashi Watanabe, Ryuji Tanosaki, Kensei Tobinai, Yoichi Takaue, Takahiro Fukuda

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The prognosis of therapy-related myelodysplastic syndrome and acute leukemia (t-MDS/AL) remains poor. We retrospectively analyzed the data of 47 patients (31 AL and 16 MDS) who were treated at our institute. Thirty-three patients received disease-adapted chemotherapy, with a response rate of 73%, while 14 received no interventions due to an indolent course, such as MDS. The median follow-up of surviving patients was 1.9 years (range 0.1-10.5) after the diagnosis of t-MDS/AL, and the estimated 3-year overall survival (OS) for all patients was 55%. Twenty-seven patients underwent allogeneic hematopoietic stem cell transplantation (HCT), and the 3-year non-relapse mortality was 17%. Twenty patients did not undergo HCT due to various reasons including advanced age or comorbidities. The 3-year OS was better in patients who received HCT than in those who did not (71 vs. 31%; p = 0.018). A multivariate analysis revealed that HCT was associated with a better OS. Although this study has several limitations, including a potential selection bias due to the retrospective nature of the analysis and a small number of patients, the results show that modern HCT may be useful for inducing long-term survival in a fraction of patients suffering from t-MDS/AL. The present findings warrant future prospective studies.

Original languageEnglish
Pages (from-to)334-341
Number of pages8
JournalInternational Journal of Hematology
Volume92
Issue number2
DOIs
Publication statusPublished - 2010 Sep
Externally publishedYes

Fingerprint

Hematopoietic Stem Cell Transplantation
Myelodysplastic Syndromes
Cell- and Tissue-Based Therapy
Leukemia
Survival
Selection Bias
Comorbidity
Therapeutics
Multivariate Analysis
Prospective Studies
Drug Therapy
Mortality

Keywords

  • Acute leukemia
  • Therapy-related myelodysplastic syndrome
  • Transplantation

ASJC Scopus subject areas

  • Hematology

Cite this

Hematopoietic stem cell transplantation for therapy-related myelodysplastic syndrome and acute leukemia : A single-center analysis of 47 patients. / Yokoyama, Hiroki; Mori, Shin Ichiro; Kobayashi, Yukio; Kurosawa, Saiko; Saito, Bungo; Fuji, Shigeo; Maruyama, Dai; Azuma, Teruhisa; Kim, Sung Won; Watanabe, Takashi; Tanosaki, Ryuji; Tobinai, Kensei; Takaue, Yoichi; Fukuda, Takahiro.

In: International Journal of Hematology, Vol. 92, No. 2, 09.2010, p. 334-341.

Research output: Contribution to journalArticle

Yokoyama, H, Mori, SI, Kobayashi, Y, Kurosawa, S, Saito, B, Fuji, S, Maruyama, D, Azuma, T, Kim, SW, Watanabe, T, Tanosaki, R, Tobinai, K, Takaue, Y & Fukuda, T 2010, 'Hematopoietic stem cell transplantation for therapy-related myelodysplastic syndrome and acute leukemia: A single-center analysis of 47 patients', International Journal of Hematology, vol. 92, no. 2, pp. 334-341. https://doi.org/10.1007/s12185-010-0640-7
Yokoyama, Hiroki ; Mori, Shin Ichiro ; Kobayashi, Yukio ; Kurosawa, Saiko ; Saito, Bungo ; Fuji, Shigeo ; Maruyama, Dai ; Azuma, Teruhisa ; Kim, Sung Won ; Watanabe, Takashi ; Tanosaki, Ryuji ; Tobinai, Kensei ; Takaue, Yoichi ; Fukuda, Takahiro. / Hematopoietic stem cell transplantation for therapy-related myelodysplastic syndrome and acute leukemia : A single-center analysis of 47 patients. In: International Journal of Hematology. 2010 ; Vol. 92, No. 2. pp. 334-341.
@article{1203b9b9bbfc4278914e6567b2a804aa,
title = "Hematopoietic stem cell transplantation for therapy-related myelodysplastic syndrome and acute leukemia: A single-center analysis of 47 patients",
abstract = "The prognosis of therapy-related myelodysplastic syndrome and acute leukemia (t-MDS/AL) remains poor. We retrospectively analyzed the data of 47 patients (31 AL and 16 MDS) who were treated at our institute. Thirty-three patients received disease-adapted chemotherapy, with a response rate of 73{\%}, while 14 received no interventions due to an indolent course, such as MDS. The median follow-up of surviving patients was 1.9 years (range 0.1-10.5) after the diagnosis of t-MDS/AL, and the estimated 3-year overall survival (OS) for all patients was 55{\%}. Twenty-seven patients underwent allogeneic hematopoietic stem cell transplantation (HCT), and the 3-year non-relapse mortality was 17{\%}. Twenty patients did not undergo HCT due to various reasons including advanced age or comorbidities. The 3-year OS was better in patients who received HCT than in those who did not (71 vs. 31{\%}; p = 0.018). A multivariate analysis revealed that HCT was associated with a better OS. Although this study has several limitations, including a potential selection bias due to the retrospective nature of the analysis and a small number of patients, the results show that modern HCT may be useful for inducing long-term survival in a fraction of patients suffering from t-MDS/AL. The present findings warrant future prospective studies.",
keywords = "Acute leukemia, Therapy-related myelodysplastic syndrome, Transplantation",
author = "Hiroki Yokoyama and Mori, {Shin Ichiro} and Yukio Kobayashi and Saiko Kurosawa and Bungo Saito and Shigeo Fuji and Dai Maruyama and Teruhisa Azuma and Kim, {Sung Won} and Takashi Watanabe and Ryuji Tanosaki and Kensei Tobinai and Yoichi Takaue and Takahiro Fukuda",
year = "2010",
month = "9",
doi = "10.1007/s12185-010-0640-7",
language = "English",
volume = "92",
pages = "334--341",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Hematopoietic stem cell transplantation for therapy-related myelodysplastic syndrome and acute leukemia

T2 - A single-center analysis of 47 patients

AU - Yokoyama, Hiroki

AU - Mori, Shin Ichiro

AU - Kobayashi, Yukio

AU - Kurosawa, Saiko

AU - Saito, Bungo

AU - Fuji, Shigeo

AU - Maruyama, Dai

AU - Azuma, Teruhisa

AU - Kim, Sung Won

AU - Watanabe, Takashi

AU - Tanosaki, Ryuji

AU - Tobinai, Kensei

AU - Takaue, Yoichi

AU - Fukuda, Takahiro

PY - 2010/9

Y1 - 2010/9

N2 - The prognosis of therapy-related myelodysplastic syndrome and acute leukemia (t-MDS/AL) remains poor. We retrospectively analyzed the data of 47 patients (31 AL and 16 MDS) who were treated at our institute. Thirty-three patients received disease-adapted chemotherapy, with a response rate of 73%, while 14 received no interventions due to an indolent course, such as MDS. The median follow-up of surviving patients was 1.9 years (range 0.1-10.5) after the diagnosis of t-MDS/AL, and the estimated 3-year overall survival (OS) for all patients was 55%. Twenty-seven patients underwent allogeneic hematopoietic stem cell transplantation (HCT), and the 3-year non-relapse mortality was 17%. Twenty patients did not undergo HCT due to various reasons including advanced age or comorbidities. The 3-year OS was better in patients who received HCT than in those who did not (71 vs. 31%; p = 0.018). A multivariate analysis revealed that HCT was associated with a better OS. Although this study has several limitations, including a potential selection bias due to the retrospective nature of the analysis and a small number of patients, the results show that modern HCT may be useful for inducing long-term survival in a fraction of patients suffering from t-MDS/AL. The present findings warrant future prospective studies.

AB - The prognosis of therapy-related myelodysplastic syndrome and acute leukemia (t-MDS/AL) remains poor. We retrospectively analyzed the data of 47 patients (31 AL and 16 MDS) who were treated at our institute. Thirty-three patients received disease-adapted chemotherapy, with a response rate of 73%, while 14 received no interventions due to an indolent course, such as MDS. The median follow-up of surviving patients was 1.9 years (range 0.1-10.5) after the diagnosis of t-MDS/AL, and the estimated 3-year overall survival (OS) for all patients was 55%. Twenty-seven patients underwent allogeneic hematopoietic stem cell transplantation (HCT), and the 3-year non-relapse mortality was 17%. Twenty patients did not undergo HCT due to various reasons including advanced age or comorbidities. The 3-year OS was better in patients who received HCT than in those who did not (71 vs. 31%; p = 0.018). A multivariate analysis revealed that HCT was associated with a better OS. Although this study has several limitations, including a potential selection bias due to the retrospective nature of the analysis and a small number of patients, the results show that modern HCT may be useful for inducing long-term survival in a fraction of patients suffering from t-MDS/AL. The present findings warrant future prospective studies.

KW - Acute leukemia

KW - Therapy-related myelodysplastic syndrome

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=77956894757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956894757&partnerID=8YFLogxK

U2 - 10.1007/s12185-010-0640-7

DO - 10.1007/s12185-010-0640-7

M3 - Article

VL - 92

SP - 334

EP - 341

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 2

ER -